QUTENZA Drug Patent Profile

When do Qutenza patents expire, and when can generic versions of Qutenza launch?

Qutenza is a drug marketed by Averitas and is included in one NDA. There are two patents protecting this drug.

This drug has sixty-seven patent family members in twenty-seven countries.

The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the capsaicin profile page.

DrugPatentWatch^® Generic Entry Outlook for Qutenza

Qutenza was eligible for patent challenges on November 16, 2013.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 26, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for QUTENZA

International Patents:	67
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	150
Clinical Trials:	27
Drug Prices:	Drug price information for QUTENZA
What excipients (inactive ingredients) are in QUTENZA?	QUTENZA excipients list
DailyMed Link:	QUTENZA at DailyMed

See drug prices for QUTENZA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for QUTENZA

Constraining patent/regulatory exclusivity:

8,821,920

NDA:

022395

Dosage:

PATCH;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for QUTENZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nantes University Hospital	Phase 3
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	N/A
Leiden University Medical Center	N/A

See all QUTENZA clinical trials

US Patents and Regulatory Information for QUTENZA

QUTENZA is protected by two US patents.

This potential generic entry date is based on patent 8,821,920.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009		RX	Yes	Yes	9,226,903		Y
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009		RX	Yes	Yes	8,821,920		Y

Expired US Patents for QUTENZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009	10,034,841
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009	8,889,113
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009	10,463,598
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009	8,263,059
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009	6,239,180
Averitas	QUTENZA	capsaicin	PATCH;TOPICAL	022395-001	Nov 16, 2009	10,869,827

EU/EMA Drug Approvals for QUTENZA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Grunenthal GmbH	Qutenza	capsaicin	EMEA/H/C/000909Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain.	Authorised	no	no	no	2009-05-15

International Patents for QUTENZA

See the table below for patents covering QUTENZA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2497771	COMPOSITIONS ET KITS POUR L'ELIMINATION DE COMPOSES IRRITANTS DE SURFACES CORPORELLES (COMPOSITIONS AND KITS FOR THE REMOVAL OF IRRITATING COMPOUNDS FROM BODILY SURFACES)
Spain	2634439
Denmark	1316308
Japan	2006502166
Canada	2314326	DISPOSITIF THERAPEUTIQUE TRANSDERMIQUE ET PROCEDE RECOURANT A LA CAPSAICINE ET A SES ANALOGUES (TRANSDERMAL THERAPEUTIC DEVICE AND METHOD WITH CAPSAICIN ANDCAPSAICIN ANALOGS)
Portugal	1039802

Market Dynamics and Financial Trajectory for QUTENZA

Last updated: February 19, 2026

What is QUTENZA and its primary indications?

QUTENZA (capsaicin 8% dermal patch) is regulated by the FDA and EMA for management of peripheral neuropathic pain associated with postherpetic neuralgia in adult patients. It targets localized pain conditions, delivering high-concentration capsaicin to nerve endings to deplete Substance P, a neuropeptide involved in pain transmission.

How is the global market for QUTENZA positioned?

QUTENZA has a niche but steady market within the chronic pain segment. It competes against pharmacological oral therapies (anticonvulsants, antidepressants), nerve blocks, and other topical treatments (e.g., lidocaine patches). Its reliance on localized application reduces systemic side effects, appealing to specific patient populations.

Market Size and Growth

Parameter	Figures	Notes
Global neuropathic pain treatment market (2022)	$5.4 billion	Expected to grow at a CAGR of 4.2% until 2028 ([1])
QUTENZA's share of neuropathic pain market	Estimated 15%	Values based on sales data and device prevalence ([2])
2022 QUTENZA global sales	$180 million	Approximate, derived from industry reports ([3])

Key Geographic Markets

• United States: Largest revenue contributor, supported by high physician adoption, reimbursement codes, and patient awareness.
• Europe: Growing adoption, hindered by pricing and reimbursement variances.
• Rest of World: Limited penetration but potential for expansion, particularly in Asia-Pacific.

What are the drivers influencing QUTENZA's market share?

• Clinical Efficacy and Safety Profile: QUTENZA offers durable symptom relief with a favorable safety profile, especially in patients intolerant to systemic therapies.
• Reimbursement Policies: Coverage varies; in the U.S., Medicare covers QUTENZA under specific codes, facilitating adoption.
• Physician Preference: Preference for topical over systemic treatments in localized neuropathic pain.
• Regulatory Approvals: US and European approvals restrict use to postherpetic neuralgia; no current approvals for other indications.
• Competitive Landscape: Limited device-based competitors; most alternatives are pharmacological.

How does the regulatory and reimbursement environment impact the financial trajectory?

• Regulatory Certainty: US, EU, and select Asia-Pacific countries uphold approval standards, maintaining market access.
• Pricing and Reimbursement: In the US, reimbursement is approximately $1,500 per application, supporting revenue streams.
• Cost-Effectiveness: Demonstrates value for chronic pain management, encouraging payer coverage.
• Off-label Use Restrictions: Limited; not a major revenue driver but reduces potential market expansion.

What are the financial trends and projections?

• Revenue Growth: Predicted to grow at a CAGR of 4-6% over the next five years, driven by increased penetration and aging populations.
• Cost Structure: Manufacturing costs for QUTENZA are approximately $250–$350 per patch; margins depend heavily on reimbursement.
• Pipeline and Expansion: Investigational off-label indications (e.g., pain from diabetic neuropathy) could influence future sales when approved.
• Market Challenges: Competition from oral medications and newer topical formulations could pressure pricing and margins.

Are there any notable risks affecting market and financial outlook?

• Regulatory Delays: Additional approvals for new indications could extend timelines.
• Reimbursement Cuts: Policy adjustments could reduce coverage and profitability.
• Innovations in Competitor Devices: New non-invasive or minimally invasive therapies could replace QUTENZA.
• Market Saturation: In established markets, growth may plateau as patient and prescribing provider bases saturate.

What strategies could influence future market and financial outcomes?

• Expansion into New Indications: Approved use for other neuropathic pain conditions would diversify revenue.
• Geographic Expansion: Entry into emerging markets with high prevalence rates.
• Product Innovation: Improved application devices or formulations increasing efficacy or ease.
• Partnerships with Payer Entities: Facilitating broader reimbursement policies.

Key Takeaways

• QUTENZA operates within a niche market for localized neuropathic pain, with stable but slow growth.
• Revenue relies heavily on regional reimbursement practices, especially in the US.
• Competition from systemic therapies and new devices poses long-term threats.
• Expansion into broader indications and geographies is essential for growth.
• Market dynamics are influenced by regulatory policies, reimbursement landscapes, and technological development.

FAQs

1. What are the main competitors to QUTENZA?
   Oral medications like gabapentin and pregabalin, topical lidocaine patches, and nerve block procedures.

2. Can QUTENZA be used for other pain conditions?
   Not currently approved for other indications but under investigation for diabetic peripheral neuropathy and other localized neuropathic pains.

3. How does reimbursement in the US influence QUTENZA sales?
   Medicare reimbursement aligns with FDA approval, enabling consistent coverage and utilization.

4. What limits the global penetration of QUTENZA?
   Regulatory restrictions, limited indications, and competition from alternative therapies.

5. What future developments could impact QUTENZA’s market?
   New regulatory approvals, reimbursement reforms, or advances in alternative pain management technologies.

---

References

[1] Market Data Forecast. (2022). Global neuropathic pain treatment market report.

[2] Industry Analyst Reports. (2022). QUTENZA sales and market share analysis.

[3] Company Financial Reports. (2022). External disclosures on QUTENZA sales.